Regulus Therapeutics Unternehmenskultur

Ms. Allison Wey has been a Vice President of Investor Relations and Corporate Communications at Regulus Therapeutics Inc. since May 23, 2016. Ms. Wey has more than 25 years of experience in investor relations, financial communications and corporate communications. She served as Vice President of Investor Relations and Public Affairs at Durata Therapeutics, Inc. since October 15, 2012. Ms. Wey served as Vice President of Investor Relations & Corporate Affairs at Par Pharmaceutical Companies Inc. She served as Senior Director of Investor Relations and Corporate Affairs of Strativa Pharmaceuticals Inc. Ms. Wey served as Senior Director of Investor Relations & Corporate Affairs; Senior Director of Investor Relations and Vice President of Investor Relations. She served as Vice President of Investor Relations and Corporate Communications at Boron, LePore & Associates, Inc. She served as Senior Vice President of Edelman Financial Worldwide; Managing Director of Financial Communications Group, Hill and Knowlton; Director of Aftermarket Services, Equity Capital Markets at Bear, Stearns & Co., Inc. and Trading Floor Reporter for the American Stock Exchange. Ms. Wey earned her B.A. in Economics/Marketing from Drake University.

Mr. Daniel R. Chevallard, also known as Dan, CPA, has been the Chief Financial Officer at Regulus Therapeutics Inc. since May 4, 2017. Mr. Chevallard served as Vice President of Finance & Accounting at Regulus Therapeutics Inc. since May 2013 until May 4, 2017. Mr. Chevallard is a corporate finance leader with public accounting expertise. Mr. Chevallard served in senior roles in Corporate Finance, Accounting and Financial Reporting as a Corporate Controller and Senior Director of Finance at Prometheus Laboratories Inc. Mr. Chevallard was a Senior Financial Auditor at Ernst & Young LLP.

Dr. Timothy Michael Wright, also known as Tim, M.D., Ph.D., has been Chief Research and Development Officer of Regulus Therapeutics Inc. since October 5, 2016. Dr. Wright oversees Regulus' research, drug discovery, clinical development and regulatory affairs functions. He has been General Counsel and Secretary of National Standard Company Inc. since 1996. He serves as a key scientific advisor to several organizations, including the Bill & Melinda Gates Foundation. He served as an Executive Vice-President of Translational Sciences at the California Institutes for Biomedical Research (Calibr) since February 2015. He served as Head of Exploratory Development for Novartis AG from 2011 to January 2015. He served as the Global Head of Development at Novartis Pharmaceuticals Corporation since November 9, 2011 until August 1, 2014. He served a variety of positions with increasing levels of responsibility over 11-year period at Novartis Pharma. He joined Novartis in 2004 and served as Senior Vice President and Global Head of Translational Sciences at Novartis Institutes for BioMedical Research. Prior to Novartis, he spent three years (from 2001 to 2004) at Pfizer holding leadership positions in Discovery and Clinical Sciences, leading translational research efforts and clinical trials for numerous programs across several therapeutic areas. He served for Pfizer Global Research and Development as the Exploratory Therapy Area Leader for Inflammation. He served as Chief of the Division of Rheumatology and Clinical Immunology and an endowed professor at the University of Pittsburgh until 2001. He has been an Independent Director of ENYO Pharma SAS since November 7, 2016. He serves as a Director of Schr???dinger, LLC. He is a physician-scientist trained at the University of Delaware (BA in Biology) and the Johns Hopkins University School of Medicine (MD, Post-doctoral training).

Lisa Melia serves as the Vice President, Clinical Operations of Regulus Therapeutics. Lisa started at Regulus Therapeutics in Sep of 2017. Lisa currently resides in the Greater San Diego Area.

Christopher Aker serves as the Vice President, Legal Affairs of Regulus Therapeutics. Christopher started at Regulus Therapeutics in Jan of 2016. Christopher currently resides in the Greater San Diego Area.

Kathleen G serves as the Vice President, Research of Regulus Therapeutics. Kathleen started at Regulus Therapeutics in May of 2018. Kathleen currently resides in the Greater San Diego Area.

Dan Chevallard serves as the Chief Financial Officer of Regulus Therapeutics. Dan started at Regulus Therapeutics in May of 2017. Dan currently resides in the Greater San Diego Area.

Timothy Wright serves as the Chief Research and Development Officer of Regulus Therapeutics. Timothy started at Regulus Therapeutics in October of 2016. Timothy currently resides in the Greater San Diego Area.